Informations générales (source: ClinicalTrials.gov)
Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism
Interventional
Phase 3
Assistance Publique Hopitaux De Marseille (Voir sur ClinicalTrials)
septembre 2011
mars 2017
29 juin 2024
Atherosclerotic cardiovascular disease (ASCD) is the first cause of morbidity and
mortality in insulin resistant states. The typical dyslipidemia that is associated with
insulin resistance, which includes a postprandial increase of triglyceride-rich
lipoproteins (TRL) with excess of intestinal triglyceride-rich-lipoprotein-apoB-48
(TRL-apoB-48), is felt to play an important role in the accelerated ASCD. Recently,
intestinal TRL-apoB-48 overproduction appeared as a newly recognized component of insulin
resistance. There is only a limited amount of information in the literature regarding the
factors and the mechanisms modulating the metabolism of intestinal TRL-apoB-48 in the
setting of insulin resistance
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Assistance Publique Hopitaux de Marseille - 13354 - Marseille - France | rene Valero | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
Male or feminine
- age from 18 to 70 years
- deficit in growth hormone informed by a peak lower than 10 mUI / l in answer to a
test of hypoglycemia (or another test of stimulation if the hypoglycemia insulinique
is dissuaded) (cf. attached the RCP of various growth hormone used at the adult)
- centre (treatments optimized previously will be maintained during all the duration
of the study) thyréotrope, corticotrope and gonadotrope substituted well for at
least 6 months
- IMC(CEREBRAL-MOTOR HANDICAPPED) < 30 kg / m2
- fasting blood glucose < 1,26 g/L
- clearance of the creatinine > 60 ml / min
Male or feminine
- age from 18 to 70 years
- deficit in growth hormone informed by a peak lower than 10 mUI / l in answer to a
test of hypoglycemia (or another test of stimulation if the hypoglycemia insulinique
is dissuaded) (cf. attached the RCP of various growth hormone used at the adult)
- centre (treatments optimized previously will be maintained during all the duration
of the study) thyréotrope, corticotrope and gonadotrope substituted well for at
least 6 months
- IMC(CEREBRAL-MOTOR HANDICAPPED) < 30 kg / m2
- fasting blood glucose < 1,26 g/L
- clearance of the creatinine > 60 ml / min
Nobody particularly protected: incapable major and private person of freedom, person
hospitalized for another pathology; · nobody mastering the reading of the French language
- carrier patients of a tumor in service
- pregnant woman